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Abstract
Objectives: To assess HIV-1 diversity, transmission dynamics and prevalence of
transmitted drug resistance (TDR) in Angola, five years after ART scale-up.
Methods: Population sequencing of the pol gene was performed on 139 plasma
samples collected in 2009 from drug-naive HIV-1 infected individuals living in
Luanda. HIV-1 subtypes were determined using phylogenetic analysis. Drug
resistance mutations were identified using the Calibrated Population Resistance
Tool (CPR). Transmission networks were determined using phylogenetic analysis
of all Angolan sequences present in the databases. Evolutionary trends were
determined by comparison with a similar survey performed in 2001.
Results: 47.1% of the viruses were pure subtypes (all except B), 47.1% were
recombinants and 5.8% were untypable. The prevalence of subtype A decreased
significantly from 2001 to 2009 (40.0% to 10.8%, P50.0019) while the prevalence
of unique recombinant forms (URFs) increased.2-fold (40.0% to 83.1%,
P,0.0001). The most frequent URFs comprised untypable sequences with
subtypes H (U/H, n57, 10.8%), A (U/A, n56, 9.2%) and G (G/U, n54, 6.2%). Newly
identified U/H recombinants formed a highly supported monophyletic cluster
suggesting a local and common origin. TDR mutation K103N was found in one
(0.7%) patient (1.6% in 2001). Out of the 364 sequences sampled for transmission
network analysis, 130 (35.7%) were part of a transmission network. Forty eight
transmission clusters were identified; the majority (56.3%) comprised sequences
sampled in 2008–2010 in Luanda which is consistent with a locally fuelled
epidemic. Very low genetic distance was found in 27 transmission pairs sampled in
the same year, suggesting recent transmission events.
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Conclusions: Transmission of drug resistant strains was still negligible in Luanda
in 2009, five years after the scale-up of ART. The dominance of small and recent
transmission clusters and the emergence of new URFs are consistent with a rising
HIV-1 epidemics mainly driven by heterosexual transmission.
Introduction
Despite the recent decline in the number of people newly infected with HIV,
around 35.3 million people were still living with HIV at the end of 2012 [1]. Sub-
Saharan Africa remains severely affected by the epidemic accounting for 71% of
the people living with HIV in the world and for 69.5% of the new infections [1].
Angola is a South-western African country bordered by Republic of Congo,
Democratic Republic of Congo, Zambia and Namibia. According to the UNAIDS
report on the global AIDS epidemic 2013 [1] the estimated HIV prevalence and
new infections in adults have decresead between 2001 and 2012 in all the
bordering countries of Angola. For example, in the Republic of Congo HIV
prevalence decreased from 4.7% to 2.8% and the number of new infections
decreased from 6,600 to 3,400. In contrast, the estimated number of adults living
with HIV in Angola has increased in the same period from 110,000 to 220,000
(1.8% vs 2.3% prevalence) and the estimated number of new infections rose from
16,000 to 23,000 [1]. However a recent HIV seroprevalence survey performed on
pregnant women in 36 sentinel sites in 18 provinces of Angola has found that on
aggregate HIV prevalence did not vary significantly from 2004 up to 2011 (median
2.8%, range 2.7%–3.2%) although there was considerable variation across
provinces [2]. Additional studies are clearly needed to better characterize the
dynamics of the HIV epidemic in Angola.
HIV-1 epidemic in Angola is highly complex with all HIV-1 group M subtypes
(except B), several circulant recombinant forms (CRFs), unique recombinant
forms (URFs) and untypable (U) strains reported [3, 4, 5, 6]. This genetic
complexity may pose a significant challenge to laboratory diagnosis and
antiretroviral treatment (ART) effectiveness [7, 8], underscoring the importance
of implementing regular surveys of HIV-1 diversity and its impact in this country.
Transmitted drug resistance (TDR) is a major public health problem, especially
in resource-limited settings as it can determine rapid loss of effectiveness of first-
line antiretroviral (ARV) regimens [9, 10]. Drug-naive individuals that acquire a
virus with drug resistance mutations (DRMs) begin ART with a higher risk of
virologic failure and of developing resistance [9, 11]. The absence of proper
patient monitoring may lead to increased emergence and transmission of resistant
strains [12]. ART has been available in Angola since 2000 for those infected with
HIV who could buy ARV drugs. Since 2004, a national plan has been
implemented to provide free ARV drugs to HIV-1 infected individuals using the
WHO public health approach to ARV delivery [13]. At the end of 2012 the
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number of people on ART was 39,704 [1], 48% of the adults in need of treatment
based on WHO 2010 guidelines [14]. The frequency of TDR in Angolan patients
has risen from 1.6% in 2001 [15] to 16.3% in 2008–2010 [4] suggesting that TDR
may be an important public health problem in Angola. However, further work is
required to characterize TDR level in Luanda as only a few patients living in this
province have been included in previous surveys.
In this study we aimed to better characterize the genetic diversity of HIV-1 and
determine the prevalence of TDR in drug-naive patients in Luanda five years after
ART scale-up in 2009. Additionally, to better understand the dynamics of the
HIV-1 epidemics we performed the first investigation of HIV-1 transmission
networks in Angola.
Materials and Methods
Study population
One hundred and thirty nine plasma samples were collected during 2009 from
drug-naive HIV-1 positive individuals attending the Hospital da Divina
Provideˆncia (HDP) in Luanda, Angola. This hospital is located in the Kilamba-
Quiaxe district serving an estimated population of 990,892 inhabitants, 13.4% of
Luanda’s population (7,395,977 habitants) [16]. Besides the patients attended at
the main building, the hospital works with patients attending four health centers
located in different regions of Luanda. The main criteria for patient inclusion in
the study were those recommended by the WHO for this type of study [12]:
confirmed diagnosis of HIV-1 infection, no pregnancy or first pregnancy (to
exclude previous use of ARV for the prevention of mother-to-child transmission
during delivery), no clinical diagnosis of AIDS (stage 1 and 2 WHO classification
system for HIV infection) and no ART exposure. Epidemiological, clinical, and
virological characterization of the patients is given in Table 1.
Serological diagnosis of HIV-1 infection was done using the rapid tests
Determine HIV-1/2 (Abbott) and Uni-Gold Recombigen (Trinity Biotech). The
number of CD4+ T cells was determined using the ABACUS 5 Junior Hematology
analyzer. Plasma viral load was determined in a subset of patients using the
Abbott Real Time HIV-1 assay (Abbott Laboratories).
The study was conducted according to the Declaration of Helsinki and was
reviewed and approved by the Board of Directors of Hospital da Divina
Provideˆncia (Luanda, Angola) and the National Ethics Committee of Angola.
Written informed consent was obtained from all participants. The study was
verbally explained to the patients before they signed the written consent.
For the transmission network study, to avoid overestimation of relatedness
between sequences due to the use of scarce data [17] we extended the study
population to all other Angolan patients for which pol sequences were available in
the Los Alamos HIV Sequence Database [18]. Hence, in addition to our present
sequences we used 226 Angolan pol sequences collected from the Los Alamos HIV
Sequence Database, counting in total 364 sequences. These sequences were derived
Diversity and Evolution of HIV-1 in Angola
PLOS ONE | DOI:10.1371/journal.pone.0113626 December 5, 2014 3 / 17
from samples collected in 1993 and 2001 (n586) [6], 2009 (n539) [18] and 2008-
2010 (n5101) [4]. Most sequences (n564, 28.3%) were obtained from patients
attending different medical facilities in and near Luanda (including Hospital
Sanato´rio de Luanda, Laborato´rio da Forc¸a Ae´rea Nacional Angolana, Hospital
Militar Principal, Clı´nica Sagrada Esperanc¸a, Centro Nacional de Sangue and Sa˜o
Lucas Medical Center in the village Kifangondo). Remaining sequences were
obtained from patients attending Hospital services in Cabinda (n520, 8.8%),
Namibe (n54, 1.8%), Benguela (n54, 1.8%), Zaire (n53, 1.3%), Cuanza Norte,
Bengo and Huila (n51, 0.4%, each), and from patients living in Central (n57,
3.1%), North (n53, 1.3%) and South (n52, 0.9%) of Angola. Origin of 116
(51.3%) patients was not available. Fourteen patients were on ART. Because HIV
transmission networks are mainly confined to a country [19] no sequences outside
Angola were included in the present study.
Viral RNA extraction, PCR amplification and sequencing
Viral RNA was extracted from 140 ml plasma using QIAmp Viral RNA Mini Kit
(Qiagen). RT-PCR was performed with Titan One Tube RT-PCR System (Roche).
Nested PCR was done using an in-house method described elsewhere [15, 20].
Thermal cycling conditions for PCR and primers sequence and position were
previously described [15, 20]. DNA sequences were obtained with Big Dye
Terminator Cycle Sequencing Kit (Applied Biosystems) and an automated
sequencer (3100-Avant Genetic Analyzer, Applied Biosystems).
Table 1. Epidemiological, clinical, and virological characteristics of HIV-1 Angolan patients analyzed in this study.
Variables Samples
Patients [n (%)] 139 (100)
Age [mean (SD), years] 36 (14) (n5139)
Gender [n (%)]
Male 50 (36.0)
Female 87 (62.6)
Unknown 2 (1.4)
Transmission route [n (%)]
Heterosexual 120 (86.3)
Vertical 14 (10.1)
Blood transfusion 2 (1.4)
Unknown 3 (2.2)
CD4 [mean (range), cells/ml] 240.5 (1–1914) (n5106)
HIV RNA [mean, (SD) log10, copies/ml] 5.1 (1.0) (n586)
Pure subtype [n (%)] 65 (47.1) (n5138)
Untypable 8 (5.8) (n5138)
Recombinants [n (%)] 65 (47.1) (n5138)
doi:10.1371/journal.pone.0113626.t001
Diversity and Evolution of HIV-1 in Angola
PLOS ONE | DOI:10.1371/journal.pone.0113626 December 5, 2014 4 / 17
Phylogenetic and recombination analysis
Sequences were aligned with reference strains collected from the Los Alamos HIV
Sequence Database [18] using ClustalX [21]. Maximum-likelihood (ML)
phylogenetic analyses [22] were performed using the best-fit model of molecular
evolution estimated by Modeltest v3.7 under the Akaike information criterion
[23]. ML trees were inferred, with program PhyML using Seaview software [24].
To find the ML tree, an iterative heuristic method combining two different tree
rearrangement methods was used: nearest neighbor interchange (NNI) and
subtree pruning and regrafting (SPR). The reliability of the obtained topology was
estimated with the approximate likelihood-ratio test (aLRT) [24]. Recombination
analysis was performed by bootscanning using SimPlot [25].
For transmission network analysis, protease (PR) and reverse transcriptase (RT)
sequences were concatenated in SeaView [24]. Sequences were aligned with
ClustalX [21] and manually edited in MEGA [26]. Codons associated to drug
resistance were stripped from the alignment to exclude convergent evolution [9].
Phylogenetic analysis was performed using a single alignment with all subtypes
and CRFs included as previously described [19, 27]. Best-fit model was chosen
with Modeltest v3.7 under the Akaike information criterion [23]. ML tree was
constructed in PhyML incorporated in Bioportal server [28]. Reliability of the tree
was assessed using bootstrap replication (1000 replicates). Genetic distance for
clusters with bootstrap support >90% was measured in MEGA [26]. Sequences
with genetic distance ,0.05 (range 0.000–0.049) substitutions per site were
considered genetically related and patients were assumed to belong to the same
transmission cluster [29]. Automatic cluster detection was used to confirm the
transmission clusters that were initially detected. This was performed with
PhyloPart program based on Approximate ML tree obtained with FastTree
program [30]. Clusters were detected through the depth-first search of reliable
nodes with patristic distance under 1st percentile threshold of the whole tree
distance [31]. According to this threshold, transmission clusters were recognized
with patristic distance ,0.07 substitutions per site and node reliability >90%.
Resistance mutation analysis
Resistance mutation analysis was performed using the Stanford genotypic
resistance interpretation algorithm [32]. Mutations specifically associated with
transmitted HIV-1 drug resistance were analyzed with the Calibrated Population
Resistance Tool (CPR) (http://cpr.stanford.edu) [33, 34].
Statistical analysis
Statistical analysis was performed with GraphPad Prism version 5.00 for
Windows, (GraphPad Software). The Spearman rank test and linear regression
analysis were used to quantify the magnitude and direction of the correlation
between viral load and CD4+ T cells. The Mann-Whitney U test was used to
compare independent groups. The frequencies of drug resistance mutations of
Diversity and Evolution of HIV-1 in Angola
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Angolan viruses were compared with those available at the Stanford HIV Drug
Resistance Database [32] for the same subtypes using Fisher’s exact test. P-values
,0.05 were considered significant.
GenBank accession numbers
Sequences have been assigned the following GenBank accession numbers:
KF853612–KF853892.
Results
HIV-1 genetic diversity
Plasma samples were obtained from 139 HIV-1 infected individuals. The mean
age of the patients was 36 years (SD, 14) and most (62.6%) were women (Table 1).
The main route of transmission was heterosexual contact (86.3%). As expected,
plasma viral load was high in most patients (mean 5.1 log10 copies/ml) and the
number of CD4+ T cells was low (mean, 240.5 cells/ml). Viral load and CD4+ T
cells were negatively correlated (n573, Spearman r520.3319, P50.0041).
Sequencing and phylogenetic analysis of the PR region was completed
successfully for 139 (100%) patients; RT sequences were also obtained for all but
one of these patients (n5138, 99.3%). Phylogenetic analysis showed that all
viruses belonged to HIV-1 group M (Figure 1 A and B). Out of the 138 isolates for
which there was PR and RT sequences, 65 (47.1%) sequences were non-
recombinant and 65 (47.1%) were recombinant, of which 11 (16.9%) were
CRF02_AG, and 8 (5.8%) were untypable (U). The following pure subtypes and
sub-subtypes were identified: A (n53, 4.6%), A1 (n51, 1.5%), A2 (n53, 4.6%), C
(n524, 36.9%), D (n59, 13.8%), F1 (n513, 20.0%), G (n57, 10.8%), H (n53,
4.6%) and J (n52, 3.2%). Thirty different patterns of recombination were found.
Subtypes A1, A2, A3, C, D, F1, G, H, J and K, and CRF02_AG and U sequences
were involved in recombination events. Most of the recombinants (n554, 83.1%)
were URFs; in almost half of the recombinants (n531, 47.7%) one of the regions
was untypable. The most frequent URFs comprised untypable sequences with
subtypes H (U/H, n57, 10.8%), A (U/A, n56, 9.2%) and G (G/U, n54, 6.2%).
The U/H recombinants had a mean genetic distance of 0.062 substitutions per site
and formed a highly supported monophyletic cluster in both genomic regions
indicating that they share the same origin (Figure 1A and B). A similar U/H
cluster has been described recently in Angola but the Province of origin of the
patients in this cluster has not been disclosed [4]. Phylogenetic analyses revealed a
close evolutionary relatedness of all U/H sequences suggesting that the origin of
this emerging URF is Luanda (Figure 2).
The analyses of the evolution of HIV-1 genetic diversity in Luanda from 2001 to
2009, showed that there was a significant decrease in the prevalence of subtype A
(3.7 fold difference, P50.0019) which was replaced by subtype C as the dominant
Diversity and Evolution of HIV-1 in Angola
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subtype (Table 2). Moreover, the percentage of URFs increased more than twice
during the same period (P,0.0001).
Drug resistance mutations and other polymorphisms
There were no major mutations associated with resistance to protease inhibitors
(PIs). The minor resistance mutations L10I and L10V, associated with resistance
to most of the PIs when present with other mutations [35, 36], were found in
15.7% and 17.6% of the isolates, respectively (Table S1). This is higher than the
frequencies previously described for untreated patients (6.8% and 8.2%) [32].
V11I, associated with resistance to darunavir [36, 37], was detected in 7.7% of
subtype F isolates and 13.3% of CRF02_AG isolates. This frequency is significantly
higher than that found in sequences of the same subtypes available in the Stanford
Database [32] (Table S1). K20I was found in almost all G and CRF02_AG isolates
and is a natural polymorphism of both genetic forms [38]. K20V was found in one
patient harboring a CRF02_AG virus. K20I/V codons are nonpolymorphic in
most subtypes [32, 39]. They appear to be selected most commonly by nelfinavir
and to reduce its susceptibility [40, 41]. A71T was found in one patient infected
with a subtype C virus and A71V was found in two patients infect with subtype D.
The latter mutation has never been described for subtype D [32]. A71T/V are
polymorphisms that occur in 2–3% of untreated individuals but the frequency
increases in patients receiving PIs [42, 43, 44]. In subtype D isolates the frequency
of polymorphism I13V was significantly lower than that found in sequences of the
same subtype available in the Stanford database [32] (Table S1). Similar findings
were obtained for K14R, E35D and R57K in subtype A and for L89M in subtype
G. For all the other polymorphisms the frequencies found in the Angolan isolates
were significantly higher when compared with the worldwide sequences available
from untreated patients [32]. Subtype F isolates were the most polymorphic
followed by subtype A and CRF02_AG.
In the RT, we detected the K103N mutation in one patient (1/138, 0.7%) that
was infected with a subtype G virus (Table S2). This mutation confers high-level
resistance to nevirapine, delavirdine and efavirenz [32]. In subtype F the
frequency of polymorphisms A272P and I326V was significantly lower than that
found in sequences of the same subtype available in the Stanford Database [32].
Similar findings were obtained for K11T, D123AS, K173S, Q174K, V179I, Q207E,
R211S, T286A, E312D and G335DE in subtype A, I293V, I329L and G335D in
subtype C and T200A, V292I and G335D in CRF02_AG. For all the other
polymorphisms the frequencies found in the Angolan isolates were significantly
higher when compared with the sequences available from untreated patients
Figure 1. Genetic subtypes and evolutionary relationships of the viruses sequenced in this study.
Maximum likelihood phylogenetic trees of PR (A) and RT (B) regions were constructed with reference
sequences from all HIV-1 subtypes and sub-subtypes (empty circles) and with the Angolan sequences (filled
circles). In each tree, the aLRT values supporting the internal branches defining a subtype or a sub-subtype
are shown. The scale represents number of base substitutions per site.
doi:10.1371/journal.pone.0113626.g001
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Figure 2. Evolutionary relationships of the U/H recombinants. Sequences of U/H recombinants (named with 09AOHDP) were aligned with those of a
previous study (named gb, GenBank)[4]._ENREF_4 The aLRT values supporting the internal branches defining a subtype or a sub-subtype are shown. The
scale represents number of base substitutions per site.
doi:10.1371/journal.pone.0113626.g002
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worldwide. Compared with the 2001 survey there was a 2.3-fold decrease in the
prevalence of TDR (1.6% vs 0.7%).
Transmission network analysis
To better characterize the dynamics of the current HIV-1 epidemics in Angola and
assist in the implementation of more focused prevention strategies we performed
a transmission network analysis. The majority of the 364 sequences included in
this sub-study were from patients residing in Luanda (n5202, 55.5%); the
remaining sequences were derived from patients from seven other provinces of
Angola (n546, 12.6%) or their origin was unknown (n5116, 31.9%).
Forty eight transmission clusters were identified comprising 130 patient
sequences (35.7% of the sampled patients) (Figure 3); more than half of these
(52.3%) reported being heterosexual (Table S3). Consistent with this, small
clusters comprising two closely related strains were dominant (n533, 68%). Only
three large transmission chains, each comprising seven individuals, were found.
As expected, most sequences (n598, 75.4%) in the transmission clusters were
sampled in 2008, 2009 and 2010 and most clusters (N527, 56.3%) comprised
only sequences sampled in these dates (Table S3). All but one sequence (from
Namibe) with available information on the origin were from Luanda indicating
that the current epidemic is mostly sustained by local transmission. Notably, 14
(29.2%) transmission clusters comprised 2001 and 2008–2010 sequences
suggesting a long standing presence of some of the more current viruses
circulating in Luanda. In 3 (21.4%) of these clusters 2001 sequences originated
from Cabinda, Benguela and Lunda Norte Provinces.
Six clusters (12.5%) comprised only sequences sampled in 2001 and one cluster
(2.1%) comprised only sequences sampled in Cabinda in 1993 (Table S3). These
clusters were considered uninformative for the current study.
Finally, in 27 transmission pairs sampled in the same year (including pairwise
clusters within larger transmission chains) very low genetic distance was found
(median 0.005 nucleotide substitutions per site; range 0.000–0.007) suggesting
Table 2. Evolution of HIV-1 genetic diversity in Luanda from 2001 to 2009.
HIV-1 genetic forms 2001 2009 P valuea
n (%) n (%)
Pure subtypes 46/86 (53.5) 65/138 (47.1) 0.6771
Recombinants 40/86 (46.5) 65/138 (47.1)
First generation CRFs 5/40 (16) 11/65 (16.9) 0.5902
URFs 16/40 (40) 54/65 (83.1) ,0.0001
Prevalence of Subtype A 17/46 (40) 7/65 (10.8) 0.0019
Prevalence of Subtype C 15/46 (33) 24/65 (36.9) 0.6899
Prevalence of Subtype F 6/46 (13) 13/65 (20) 0.4453
a - Fisher’s exact test.
doi:10.1371/journal.pone.0113626.t002
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recent transmission events [45]. Potential sample mix-up for pairwise clusters
with 0.000 genetic distances was excluded based on visual inspection of pairwise
alignments and origin of the samples. The main features of the individuals
included in the transmission networks were no different compared to individuals
outside the transmission networks (Table 3).
Discussion
We assessed HIV-1 diversity, transmission dynamics and prevalence of TDR in
Luanda in 2009, five years after the scale-up of ART and compared these data with
our previous survey performed in 2001 [6, 15]. Individuals included in this study
Figure 3. Transmission cluster analysis. Maximum likelihood tree with the 48 transmission clusters colored in green. Maximum likelihood tree was
constructed in PhyML. Reliability of the tree was assessed using bootstrap resampling (1000 replicates). Bootstrap values and cluster number are indicated
in each cluster. A bootstrap value of 0.7 (70%) or greater indicate significant support for the clusters. The scale represents number of base substitutions per
site.
doi:10.1371/journal.pone.0113626.g003
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had a low CD4 count which was directly related with high viral load. These
features are consistent with the reported absence of ART [46, 47].
Like in 2001, no major PIs resistance mutations were found in the study
population which is consistent with the fact that first-line regimens used in
Angola do not include PIs [48]. However, some minor mutations in the PR and
many unusual polymorphisms were detected suggesting that some Angolan
isolates might have a low genetic barrier for resistance to some PIs [32]. The
K103N mutation, which confers high-level resistance to nevirapine, delavirdine
and efavirenz [32], was found in one patient accounting for a 0.7% prevalence rate
of TDR which is 2.3 fold lower compared to the 2001 survey [15]. This residual
TDR prevalence is similar to that of several African countries that also use the
public health approach to ART [49, 50, 51, 52, 53] and suggests that the most
common first-line ARV regimens will be effective in this population.
Similar to previous studies, the HIV-1 epidemic in Luanda in 2009 was highly
complex being characterized by the presence of almost all subtypes (A, C, D, F, G,
H and J; 47.1%), complex recombinants viruses (47.1%) and untypable (5.8%)
strains [3, 4, 5, 6, 54]. A high number of our sequences fall at basal positions on the
phylogenetic trees (pre-subtype branches) which is consistent with the long
standing presence of HIV-1 in Angola [6]. In addition, some strains from Angola
have little organized substructure and form weaker clusters within phylogenetic
trees than the global reference sequences, not allowing a clear distinction between
Tables 3. Demographic, immunologic and virologic characteristics of HIV-1 patients included in the transmission networks and patients outside of the
networks.
Variables Total Transmission networks Remaining patients P value
Patients [n (%)] 364 (100) 130 (35.71) 234 (64.28) -
Gender [n (%)]
Male 100 (27.47) 44 (33.85) 56 (23.93)
Female 142 (39) 47 (36.15) 95 (40.6) 0.1250a
Unknown 122 (33.52) 39 (30) 83 (35.47)
Transmission route [n (%)]
Heterosexual 194 (53.3) 68 (52.3) 126 (53.85)
Vertical 15 (4.12) 7 (5.38) 8 (3.42) 0.8208a
Others 10 (2.74) 4 (3.08) 6 (2.56)
Unknown 145 (39.83) 51 (39.23) 94 (40.17)
Origin [n (%)]
Luanda 200 (54.94) 78 (60) 122 (52.14)
Cabinda 20 (5.49) 4 (3.08) 16 (6.84) 0.2850a
Others 28 (7.69) 8 (6.15) 20 (8.55)
Unknown 116 (31.87) 40 (30.77) 76 (32.48)
CD4 [mean (range), cells/ml] 335.39 (1-1914) (n541) 300.12 (12–790) (n578) 0.7309b
HIV RNA [mean, (range) log10, copies/ml] 5.15 (1.94–7) (n533) 5.06 (1.6–6.68) (n552) 0.6391
b
a – Chi-square test; b – Mann-Whitney test;
doi:10.1371/journal.pone.0113626.t003
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subtypes. As a consequence, the current global subtype classification may not
reflect the extent of diversity in this region [55].
The prevailing subtype in 2009 in Luanda was subtype C (36.9%) followed by
sub-subtype F1 (20.0%) whereas in 2001 it was subtype A followed by subtype C
[6]. The significant decrease in the prevalence of subtype A and increase in
subtype C observed in 2009 could be explained by the increasing predominance of
subtype C in the bordering countries, namely in the south region of Democratic
Republic of Congo [56] and in Zambia [51, 57, 58]. As in 2001, almost half of our
sequences were recombinant comprising all group M subtypes as well as
CRF02_AG and U sequences. The frequency of CRFs did not change between
2001 and 2009, but the frequency of URFs more than doubled in the same period.
This is on contrast to the global and regional distribution of HIV-1 genetic forms
between 2000 and 2007, where there was a notable increase in the proportion of
CRFs and a decrease in URFs [59]. Importantly, the results indicate that the
Angolan HIV-1 epidemic is still increasing in genetic complexity and suggest high
rates of co-infection and/or superinfection [60] which is consistent with an
increasing HIV-1 incidence and prevalence [1, 2, 61]. The most common URF was
U/H found in seven strains (10.8% of the recombinants and 5.1% of the total
population). This new recombinant strain was found in unrelated patients and its
sequences clustered in a highly supported monophyletic group suggesting that it
was originally produced in Luanda. The close relationship with U/H sequences
recently reported elsewhere in Angola [4], indicates that this new recombinant is
already established in Angola. Sequencing the full-length genome of this
recombinant strain will be needed to determine if this is a new CRF.
A large number of transmission clusters were identified in this study which
included 35.7% of the analyzed samples. This is not uncommon in HIV epidemics
as within a smaller population or even globally HIV infected individuals are often
part of wide transmission networks [16, 19, 62]. Small clusters mostly comprising
two sequences were dominant over large clusters which is consistent with
heterosexual contact being the main route of transmission reported in most
patients [63]. While most transmission clusters comprised only sequences from
Luanda and were therefore consistent with a locally propelled epidemic, some
clusters contained sequences from Luanda and from other locations in Angola
consistent with a more complex origin and transmission dynamics going well
beyond the borders of the capital city. Finally, based on high sequence homology
between patients in transmission clusters, a large number of potential recent
infections were inferred. Overall, the results are consistent with a rising HIV-1
epidemic in Luanda [1, 2, 61]. Further surveys are required to obtain a clearer
picture of the dynamics of the current HIV-1 epidemics at the national level.
In conclusion, transmission of drug resistant strains was still negligible in
Luanda in 2009, five years after the scale-up of ART. The dominance of small and
recent transmission clusters and the emergence of new URFs are consistent with a
rising HIV-1 epidemics mainly driven by heterosexual transmission.
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